Moderna Stock Rises After Positive News on Cancer Vaccine
Moderna's stock jumped nearly 130 percent following positive data for a new cancer vaccine developed with Merck. The Phase 3 study showed the vaccine, combined with Keytruda, significantly lowered the risk of relapse or death in melanoma patients. Experts view this as a major milestone for the company's future market potential.
Moderna's stock recorded a significant increase after positive results for a new cancer vaccine developed in collaboration with Merck were announced. This novel vaccine, called "Intismeran autogene," is designed to address the genetic structure of the tumor. One thousand one hundred patients with malignant melanoma were examined in a Phase 3 study. The combination of the vaccine with Keytruda significantly reduced the risk of relapse or death. As a direct consequence of these developments, Moderna's share price rose by almost 130 percent. Experts see this result as a major breakthrough for Moderna's future market role.